Prevalence of Hepatitis D Virus among Hepatitis B Positive Blood Donors in Port Harcourt, Nigeria

Goodnews Nkabari Nwika *

Department of Medical Laboratory Science, PAMO University of Medical Sciences, Port Harcourt, Nigeria.

Jeremiah Zaccheus Awortu

Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

Eze Evelyn Mgbeoma

Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Introduction: The Prevalence of Hepatitis D Virus among Blood Donors   in Port Harcourt, Nigeria is a maiden epidemiological study of   Hepatitis D or delta hepatitis among the donors’ population in Port Harcourt, Rivers State. Hepatitis D (Hepatitis Delta) is a disease caused by the hepatitis D virus (HDV). It is considered to be a sub viral satellite because it can propagate only in the presence of the hepatitis B virus. The prevalence of HDV in Port Harcourt has not been reported; hence this study, bridge that knowledge gap.

Methods: Using a qualitative cross sectional study design, a general serological screening test was performed on a total of 300 blood donors recruited; 222(74.00%) males and 78 (26.00%) females, all within 20-59years. Of this number, 86(28.70%) were positive for HBV while 214(71.30%) Hepatitis B negative served as control. Samples collected were analysed at blood bank unit of the Haematology Department of the Rivers State University Teaching Hospital, Port Harcourt (RSUTH). Hepatitis B surface antigen (HBsAg), and anti-hepatitis D antibodies (anti-HDV) for the presence of HBV and HDV infections were detected by one step Hepatitis B surface antigen (HBsAg) in serum, and enzyme linked immunosorbent assay for the detection of HDV as described by the www.elabScience.com (16).

Results: Of the 300 subjects, 86(28.6%) were positive for Hepatitis B surface antigen (HBsAg). Of these HBV positive subject, 9(10.4%) were positive for Hepatitis D virus (HDV). Age and gender of the study participants were not found to be risk factors for its prevalence (p > 0.05). There was no statistically significant difference in the PCV of those infected when compared with the non infected group. Using Pearson correlation analysis, HDV was not found to associate significantly with PCV (r = 0.2849, p > 0.05). This study recorded HDV prevalence rate of 10.4% among the HBsAg positive blood donors.

Conclusion and Implications for Translation: There is a 10.4% prevalence of HDV among the HBsAg positive blood donors. To increase the safety level of blood products, the screening process should therefore be extended to the HDV. 

Keywords: Hepatitis B Surface Antigen (HBsAg), Hepatitis D Virus (HDV), prevalence, co-infection, super infection, genome


How to Cite

Nwika, G. N., Awortu, J. Z., & Mgbeoma, E. E. (2023). Prevalence of Hepatitis D Virus among Hepatitis B Positive Blood Donors in Port Harcourt, Nigeria. International Blood Research & Reviews, 14(4), 48–56. https://doi.org/10.9734/ibrr/2023/v14i4317


References

Center for Disease Control; 2015.

Hepatitis D. Available:www.who.int. Acceess on 2020, 09-20.

Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, Chen WS, Goyal H, Pan S, Xu HG. Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis. Gut. 2019;68(3):512–521.

Aberra H, Gordien E, Desalegn H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Gerber A, Stene-Johansen K, Øverbø J, Johannessen A. Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia. Liver Int. 2018;38(6):1000–1009.

Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E; Kyomuhangi IG, Anna M. Hepatitis D prevalence: Problems with extrapolation to global population estimates (PDF). Gut. 2020,69 (2):396–397.

U.S. National Library of Medicine. Delta Agent (hepatitis D); 2016.Available:www.Myoclinic.org

Rizzetto Mario. Hepatitis D Virus. In Wong, Robert J.; Gish Robert G. (Eds.). Clinical Epidemiology of Chronic Liver Diseases. 2020;135–148.

Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection". The Journal of Infectious Diseases. 2021; 221(10):1677–1687.

Praveen KR, Anand BS, Rahaman M, Rahaman M. Hepatitis D. Gastroenterology. 2021;56:234-237.

Magnius L, Taylor J, Mason WS, Sureau C, Dény P, Norder H. ictv virus taxonomy profile: Deltavirus". The Journal of General Virology. 2018;99(12):1565–1566

Mixson-Hayden T, et al. Hepatitis B virus and hepatitis C virus infections in United States-bound refugees from Asia and Africa. Amarican Journal of Tropical Medicine and Hygiene. 2014;90:1014–1020.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H. Sodium Taurocholateco transporting polypeptide is a functional receptor for human hepatitis B and Virus. Elife. 2017; 1:00049-00050.

Harvala H, Wong V, Simmonds P. Acute viral hepatitis - Should the current screening strategy be modified. Journal of Clinical Virology. 2014;59(3):184-187.

Uchenna CO, Henry CO, Kenneth I, Tony MA, Evaristus SC, Yeonun O, Emin JE, Osim H, Akaninyene AO. Prevalence and risk factors of Hepatitis D virus antibody among asymptomatic carriers of Hepatitis B virus: a community survey. African Health Sciences. 2022;22(1):504–510.

Belyhun Y, Liebert UG, Maier M. Clade homogeneity and low rate of delta virus despite hyperendemicity of hepatitis B virus in Ethiopia. Virology. 2017;14(1): 176.

Panel Leila K, Soheil A, Hossein F. Reasons of under-representation of Iranian women in blood donation Hematology. Transfusion and Cell Therapy. 2021; 32021(43):256-262.

World Health Organization. Revised injection safety assessment tool; 2019.Available:www.elabScience.com

Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. Journal of Hepatology. 2015, 62(2):469–76.

Malewe K, Gnatoulma K, Mounerou S. Komlan SG, Sika, D, Alexander K, Mireille P. High prevalence of hepatitis B virus infection in the age range of 20-39 Years Old Individuals in Lome. Open Virology. 2017;11:1–7.

World Health Organization, Global Hepatitis Report. 2017;201

Alexander JS, Benno K, Marc YRH, Emanuele G, Irene K, Catherine dM, Yvan H, Anna MG. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. Journal of Hepatology. 2020;73(3):523–532.

Elzouki AN, Bashir SM, Elahmer O, Elzouki I, Alkhattali F. Prevalence and risk factors of hepatitis D virus infection in patients with chronic hepatitis B infection attending the three main tertiary hospitals in Libya. Arab Journal of Gastroenterology. 2017;18(4):216– 219.